S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Skull found in '97 in remote Alaska belongs to New York man
Jury: Musk didn't defraud investors with 2018 Tesla tweets
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Why a new Alzheimer's drug is having a slow US debut
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
New California oil well ban put on hold for voters to decide
Sri Lanka marks independence anniversary amid economic woes
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Skull found in '97 in remote Alaska belongs to New York man
Jury: Musk didn't defraud investors with 2018 Tesla tweets
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Why a new Alzheimer's drug is having a slow US debut
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
New California oil well ban put on hold for voters to decide
Sri Lanka marks independence anniversary amid economic woes
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Skull found in '97 in remote Alaska belongs to New York man
Jury: Musk didn't defraud investors with 2018 Tesla tweets
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Why a new Alzheimer's drug is having a slow US debut
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
New California oil well ban put on hold for voters to decide
Sri Lanka marks independence anniversary amid economic woes
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Skull found in '97 in remote Alaska belongs to New York man
Jury: Musk didn't defraud investors with 2018 Tesla tweets
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Why a new Alzheimer's drug is having a slow US debut
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
New California oil well ban put on hold for voters to decide
Sri Lanka marks independence anniversary amid economic woes
NASDAQ:AMPH

Amphastar Pharmaceuticals - AMPH Stock Forecast, Price & News

$31.21
+0.04 (+0.13%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$31.08
$31.79
50-Day Range
$27.99
$31.21
52-Week Range
$24.75
$44.46
Volume
211,647 shs
Average Volume
186,546 shs
Market Capitalization
$1.51 billion
P/E Ratio
20.95
Dividend Yield
N/A
Price Target
$39.00

Amphastar Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
25.0% Upside
$39.00 Price Target
Short Interest
Healthy
4.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.21
Upright™ Environmental Score
News Sentiment
0.88mentions of Amphastar Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$30,240 Sold Last Quarter
Proj. Earnings Growth
12.95%
From $1.39 to $1.57 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

64th out of 1,028 stocks

Pharmaceutical Preparations Industry

24th out of 501 stocks

AMPH stock logo

About Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPH Stock News Headlines

“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Amphastar Pharmaceuticls
Amphastar: Growth Remains Intact
See More Headlines
Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPH Company Calendar

Last Earnings
11/07/2022
Today
2/04/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMPH
Employees
1,761
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$39.00
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+25.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$62.12 million
Pretax Margin
21.02%

Debt

Sales & Book Value

Annual Sales
$437.77 million
Cash Flow
$1.91 per share
Book Value
$9.31 per share

Miscellaneous

Free Float
34,895,000
Market Cap
$1.51 billion
Optionable
Optionable
Beta
0.74

Key Executives

  • Zi Ping LuoZi Ping Luo
    Chairman, COO & Chief Scientist
  • Yong Feng ZhangYong Feng Zhang
    President, Chief Executive & Scientific Officer
  • William J. PetersWilliam J. Peters
    Chief Financial Officer, Treasurer, Director & EVP
  • Jacob LiawatidewiJacob Liawatidewi
    Secretary, Director, EVP-Sales & Marketing
  • Rong ZhouRong Zhou
    Executive Vice President-Production Center













AMPH Stock - Frequently Asked Questions

Should I buy or sell Amphastar Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMPH shares.
View AMPH analyst ratings
or view top-rated stocks.

What is Amphastar Pharmaceuticals' stock price forecast for 2023?

4 equities research analysts have issued 1-year target prices for Amphastar Pharmaceuticals' stock. Their AMPH share price forecasts range from $32.00 to $44.00. On average, they expect the company's share price to reach $39.00 in the next year. This suggests a possible upside of 25.0% from the stock's current price.
View analysts price targets for AMPH
or view top-rated stocks among Wall Street analysts.

How have AMPH shares performed in 2023?

Amphastar Pharmaceuticals' stock was trading at $28.02 at the start of the year. Since then, AMPH stock has increased by 11.4% and is now trading at $31.21.
View the best growth stocks for 2023 here
.

When is Amphastar Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our AMPH earnings forecast
.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced its quarterly earnings results on Monday, November, 7th. The company reported $0.32 earnings per share for the quarter, meeting analysts' consensus estimates of $0.32. The company earned $120.13 million during the quarter, compared to the consensus estimate of $126.20 million. Amphastar Pharmaceuticals had a net margin of 15.93% and a trailing twelve-month return on equity of 16.48%.

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.36%), Lam Group Inc. (0.27%), Allspring Global Investments Holdings LLC (0.23%), Exchange Traded Concepts LLC (0.08%), Summit Global Investments (0.06%) and New York State Common Retirement Fund (0.06%). Insiders that own company stock include David Maris, Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi.
View institutional ownership trends
.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $31.21.

How much money does Amphastar Pharmaceuticals make?

Amphastar Pharmaceuticals (NASDAQ:AMPH) has a market capitalization of $1.51 billion and generates $437.77 million in revenue each year. The company earns $62.12 million in net income (profit) each year or $1.49 on an earnings per share basis.

How many employees does Amphastar Pharmaceuticals have?

The company employs 1,761 workers across the globe.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The official website for the company is www.amphastar.com. The company can be reached via phone at (909) 980-9484, via email at jasons@amphastar.com, or via fax at 909-980-8296.

This page (NASDAQ:AMPH) was last updated on 2/4/2023 by MarketBeat.com Staff